CD36

(redirected from GPIV)

CD36

a transmembrane protein present on monocytes, platelets, megakaryocytes, the umbilical vein, small-vessel endothelium, reticulocytes, and mammary epithelium that may be involved in signal transduction; expressed in myeloproliferative disorders.
Farlex Partner Medical Dictionary © Farlex 2012

CD36

A gene on chromosome 7q11.2 that encodes the fourth major platelet surface glycoprotein, which is a receptor for thrombospondin. It is acts as a cell adhesion molecule, binding to collagen, thrombospondin, anionic phospholipids, oxidised LDL, long-chain fatty acids and Plasmodium falciparum-parasitised erythrocytes.
 
Molecular pathology
Defects in CD36 cause platelet glycoprotein deficiency; genetic variations in CD36 are associated with susceptibility to coronary heart disease type 7.
Segen's Medical Dictionary. © 2012 Farlex, Inc. All rights reserved.
References in periodicals archive ?
CD36/SR-B3 CD36 is known as scavenger receptor class B member 3 (SR-B3), thrombospondin receptor, collagen receptor, platelet membrane glycoprotein IV (GPIV), GPIIIb, and fatty acid translocase (FAT).
Some experts have demonstrated that genetic polymorphisms of platelet membrane glycoproteins (GPI1, GPIba, GPIIIa, and GPIV) may influence the efficacy of aspirin or platelet responsiveness, and genetic polymorphisms of the thromboxane A2 receptor (TBXA2R), platelet-activating factor acetylhydrolase, and coagulation factor XIII were associated with platelet aggregation.
"Pressure field evaluation in microchannel junction flows through gPIV Measurement.
The accompanying inflammatory process involves invasion of damaged areas by macrophages and monocytes including histamine, serotonin, substance P, and prostaglandins that act to sensitize muscle nociceptors served by Gp111 and GpIV afferent fibers.
ITP hastaliginin patogenezinde ise trombosit yuzeyindeki GpIIbIIIa, GpIbIX, GpIaIIa, GpV, GpIV ve diger ozgul glikoproteinlere karsi IgG, IgA ve/veya IgM tipinde otoantikorlar tanimlanmistir (8).
Autoantibodies against the platelet glycoproteins (GP) IIb/IIIa, Ia/IIa, and IV and partial deficiency in GPIV in a patient with a bleeding disorder and a defective platelet collagen interaction.